[1]
A. Bertolani, R. Ravasio, P. Raimondo, and C. Jommi, “The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study”, Grhta, vol. 9, no. 1, pp. 73–81, Jul. 2022.